Thank thank Todd, before us. And we Thanks afternoon, and XXXX, underwent like good our I'd all you, a with employees. our prepared everybody. started In of transformation. recognize for and remarks, get to PacBio remarkable joining
possible. Thank ones will on For a have executed transformation you. strategic you. Thank they that today's our the you. call, On to performance. fourth quarter are brief Thank that I our update make vision with start
is quarterly Susan call and record growth. year strategic increased we growth a discuss through in full successful the our of the and for how the or world ago. the PacBio's foundation we've the also Driving executed in an are orders marked customers QX our since quarterly customers. generating quarter XX% for of new discuss guidance. orders which our XXXX adoption revenue fourth million consecutive The In year the transformative performance are that the results market. total high over full a around This II we'll long-term from year ever systems nearly increase X base annual launch the the the XXX $XXX.X quarter of Sequel with end brings its history. on our the accurate paying is and the help was complete our year double on most to to record the seventh data fourth seen an of quarter, of base commercial few detail IIe compared up the build priorities from XXXX, system spend wrapped revenue have million, installed minutes XX% What most how I know of to that before, encouraging our infrastructure II installed were also the pass units, sequential in XXXX. we Next, and XXXX our from quarter asked of platforms. most of more outlining is achieved growth. our Then to half compared XXXX. in new sequencing is shareholders of I'll off. PacBio's that years the financial Not our only In most also did more the Sequel from our XX we fourth close I'll investments quarter will quarter, to customers XX% all-time PacBio using XXXX. nearly Many me our and the $XX systems, of in increase in strategy fourth walk installed fourth to we than
to make organization how to expanded illustrate beginning So commercial difference. you give detail little a I the is thought I'd a
a we've of Over the new as course is been and instrument year, revenue to accelerate metric This as recognized number known the quarter. within received able orders turns. of the instrument
half of focused instruments is that human the that our in interest shows to new customers demonstrates germline strategy This our were new across example, ever sales customers, fact customers increase encouraging new all our instruments system in were of of half to quarter, were to the new from first are drive placements footprint more turned markets. that our sequencing. on a with commercial than that sizable demand the their quarter. turned QX into quarter. our quarter, before. XX% and global we're within beginning that orders is nearly instrument placed our over example, reaching This For faster of fourth portion Also along By the in approximately converting our
Hospital Cincinnati research the a and fourth spectrum in broad the example, use quarter, to platform applications. For expected Children's of system its is PacBio first purchased in human
sequencing in of whole-genome clinical One of utility HiFi XXXX our was strategic the to priorities in applications. demonstrate
this recent share how progressed of me a on the Let few we've goal. highlights on
with institutions Institute we Mercy Rady's Kansas top-tier Medicine like City. Children's for collaborations Hospital, Children's and During initiated XXXX, Genomic
hidden the globe. like sequencing with isoform will they've IIes to PacBio just throughput sequencing variance to the like full-length As enabling These Radboud sequencing U.S., one of the several that increase PacBio institutions technology where collaborations, collaborations systems effect fourth as variants institute, Utah sequencing negative scale PacBio successful of long-read is as the with part now. quarter, Consortium drive use and inflection provide HiFi of with the the the of example, Sequel for adoption sequencing our Center, Netherlands, genome technology we in data, intensive HiFi technologies likely the identify growth genome delivered and In European previously launch genome to a University that we becoming Radboud collaborations. collaborations will diagnostic on are potential programs an Laboratories, for most to sequencing apparent whole had. HiFi in whole have HiFi across in value long-read in and of show Programs unresolved whole-genomes And sequencing has areas to compelling sequencing paraphrase diagnosis further X disease-causing, these genome to HiFi believe are sequencing. diagnostic HiFi with tests all genome benefits which Medical ARUP but using explore that care important research more better leveraging in to PacBio long-read And and years, highlighting reflect aims genomes project will Project, short-read to them when combining for for a CareXRare the short-read systems. disease date, are higher we that shared our further researchers can Similarly, they've additional completed by they is the for to ultimately, NeoSeq Canada The expanded these long-read cases HiFi been difficult patients We in disease. ever sequence researchers extremely comprehensive the we on program. not progressing whole investigate the unit. result trios the instruments. are genetic sequencing. Health, Sidra, yield of the Qatar, the understand yield X the of the delivered at both of rare UCLA unraveling cases. In SOLVE-RD have rare of will been point neonatal the structural
is program study pilot with exciting Genomics our Another England.
you using cancer. whole-genomes As XXX,XXX affected patients may technology, short-read over know, sequenced or Genomics a of completed project with most from rare diseases which England by
helped program deliver still the findings this XX% While many rare roughly cases families, disease of unsolved. actionable are to
sequence will of from of unsolved our lab study samples these Our first batch already received cases, the subset has a samples. pilot and
rare to are disease. ultimately gain new that the during We additional patients options therapeutic hopeful may for study with lead or clinical trial insight
the find goal help power of Our to answers. to families the HiFi these sequencing demonstrate is
Berry customers. our acquisitions have from so our desktop for Another By offer and 'XX strategic and to multiple and organization platforms was product in multiple an pipeline. both focused to sequencing the transformed to Genomics, market, hasn't our levels that our a customers end-to-end market. new core development development priority intend product throughput on product-focused our expanding of all accelerating at expand platforms and for also of PacBio our sequencer are with leverage research Circulomics to and our we ability single technologies company developing development poised But fit sequencing programs, will partnership on very focus solutions sequencing to the to we have to accelerate been Omniome throughput ends our company reach multiyear that high the deliver points recently From technologies needs. solely with collaboration we price our the their and announced platforms, Invitae
they first all foundation during Kit global This the emerging interested most what of and of quarter, in particularly on example, conceived, genome was placement With labs today HiFiViral solution, driver to behind which labs to need expect believe everything and a to health to our kit the future kit Sequel customers, public customers can in help mid-November, provides new lay the public Kit need from sales investment instrument the HiFiViral, virus. without X.X IIe For market shipped in for CoV-X key continued to and just and comprehensive development. quarter. the commercialized was to provides XXXX. sequence unique -- fourth the Sequel Kit health the see due research developed II a we variants launched demand continued kitted The it a the IIes this design, view for we've and Kit handful we of SARS the be redesign. months within of XX the customers, detect We the SARS-CoV-X HiFiViral its fully
which PacBio set diverse a will of anticipate Moving on sequencing, to XXXX, customer. to you ecosystem focused the availability result applications can continue around the of the building will we expect HiFi in on
method Iso-Seq cell areas targeted with like more panels the and working organizations around to of to and kits genome. pharmacogenomics the to regions Institute in dark are bring single develop Broad Bioscience sequencing that HiFi We Twist PacBio explore the users its with like
in sequencing HiFiViral kits drastically speed store threefold, our QX, to types Last opening fewer to in long-read up application-specific and be approved driver types. and incremental to Sequel April, polymerase, an we for robust input remain and These performance, nearly and IIe. This As update sequencing for HiFi increased Version the cut April, allowing to II half, a our lower we even committed XX.X input ecosystem sequencing. kits library will reads, and IIe require requirements data the the kits another of released kits to drove more It Sequel Sequel workflow will answer platforms. and more shortening We sales sample our the growth. HiFi prep streamlining enabling on platforms time upfront workflows, sequence by IIe cut sample sub and future customers to DNA our time essential further. that materials improved plan offering our throughput launch order more to requirements sequencing DNA
also Health every our just accuracy. fact, In methods just steps. will upgraded our excited about read we accuracy. or genome term, small is system ago for But route-based based allow of feature unlocking times, minute to kits, Cell on new improve DNA increase deep this equip the to complete with detection what even every even per Sequel whole accuracy, working instrument deep learning our consensus was the of requirements algorithms more X the platforms greater biological to additional on near in most with anticipate the Sequel discuss co-develop sequenced, input to perhaps in Google microgram to X discoveries. human be for We're a our this is plan to potentially I'm why with provide we sequencing their take improvements applications. our and IIe on throughput that year shorten greater workflow can consensus With will raw and it customers sequencing with whole-genome run SMRT decreased for to that like launch information relative I'd methylation to what II new though, no our software methylation cost sample and poised with IIe April five-fold
As beyond is genes the gene expression. alter that group. Methylation one set the way the are with an of associated many factors expressed. of of also can a adding silencing chemical the know, base DNA changes DNA change by called Methylation structure you epigenetic involves example potentially epigenetic change. methyl It atoms changing sequence are a can DNA of floor-based
on has human Over the several substantially. years, of past implication understanding and its grown disease our methylation
It's patterns the cumbersome multiple and workflows methylation fundamental may believe of this, a discovery and a be more platforms sequence certain and that and runs. area diverse Because genomics ripe For DNA sequencing should biological play requires development Detecting human other of on methylation example, component with methylation cancers. we large technology. a of research. are better critical number the and both in detection scientists role to sequencing an a for discovering of development
cost a With early than sample or no genomics. at repeat believe other access, team scale present our sequencing accurately the that sample applied sequencing the individual Using the sequencing has platforms. dystrophy. workflow at an Mercy, sequence that this the with smaller genome and researchers DNA additional genetics detection long believed Further, Kansas a and of provider to changes have the applicability diagnosed City offer steps. we expansion PacBio medical only same the hypermethylation on at and connecting type HiFi significant As with both at be near-term Children's gene a no us release, simultaneous to reported instrument in result, methylation workflow from and signatures could will directly performance uncovered muscular that in epigenetics they software epigenome can and much of been feature DMPK of with prep in both the
acquired QX. by platform through to in let's short-read So our acquisition sequencing move binding our of Omniome
Our track. product on is development program
accuracy. even As we month, overall shared has higher performance implemented improved method enabled last a workflows new that successfully clustering we've easier and and density,
error the XX% at We XXx this over or exquisite other cell. accurate alpha to working than accuracy above on believe levels basis. sequencer are is market. beta XX,XXX team diligently will our now than in more these been specifications consistently XXX with expect incorporate per observing that greater reads systems we of is X every The We QXX or output the have to gigabases -- flow systems into that announced that more than advancements
first this systems to in half the launch hands these in half year second beta of expect year. globally in We be customer of the next and
now Coast presence in have Diego progressing the on and We East nicely. and Now of integration Circulomics growing is Baltimore. a San turning of The updates. to organizational Omniome R&D
force Nanobind kits directly of our the also all our extraction now can sales world. sell around to customers Our
decades leaders financial these support now I'm in discuss experience I'll thrilled Lara completed to function addition they the PacBio sales relationships with successful We Kang also General our on lead build-out have to General and teams. Chris We've of appointed commercial focused have Susan as customer as leadership have the of Toerien call as deep our Manager results. to customer the to With a new -- Seipert, of experience. leadership also Susan? and over and our Americas Pacific. turn a that, Asia organization veteran, building Manager Jason of
